dual agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-09. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
Tolkien's fantasy books on Middle-earth, especially The Lord of the Rings and The Silmarillion, drew on a wide array of influences, including his philological interest in language, Christianity, medievalism, mythology, archaeology, ancient and modern literature and personal experience. His philological work centred on the study of Old English literature, especially Beowulf, and he acknowledged its importance to his writings. He was a gifted linguist, influenced by Germanic, Celtic, Finnish, and Greek language and mythology. Commentators have attempted to identify many literary and topological antecedents for characters, places and events in Tolkien's writings. Some writers were important to him, including the Arts and Crafts polymath William Morris, and he undoubtedly made use of some real place-names, such as Bag End, the name of his aunt's home. He acknowledged, too, John Buchan and H. Rider Haggard, authors of Edwardian adventure stories that he enjoyed. The effects of some specific experiences have been identified. Tolkien's childhood in the English countryside, and its urbanization by the growth of Birmingham, influenced his creation of the Shire, while his personal experience of fighting in the trenches of the First World War affected his depiction of Mordor.
=== Education === The families of individuals, and society at large, who have inherited or are at risk of inheriting HD have generations of experience of HD but may be unaware of recent breakthroughs in understanding the disease, and of the availability of genetic testing. Genetic counseling benefits these individuals by updating their knowledge, seeking to dispel any unfounded beliefs that they may have, and helping them consider their future options and plans. The Patient Education Program for Huntington's Disease has been created to help educate family members, caretakers, and those diagnosed with Huntington's disease. Also covered is information concerning family planning choices, care management, and other considerations.
====== Medication assisted treatment (MAT): Opioid agonist therapy (OAT) and Opioid substitution therapy (OST) ====== Medication assisted treatment (MAT) is the prescription of legal, prescribed opioids or other drugs, often long-acting, to diminish the use of illegal opioids. Many types of MAT exist, including opioid agonist therapy (OAT) where a safer opioid agonist is employed or opioid substitution therapy (OST) which employs partial opioid agonists. However, MAT, OAT, OST are often used synonymously. Opioid agonist therapy (OAT) involves the use of a full opioid agonist treatment like methadone and is generally taken daily at a clinic. Opioid substitution therapy (OST) involves the use of the partial agonist buprenorphine or a combination of buprenorphine/naloxone (brand name Suboxone). Oral/sublingual formulations of buprenorphine incorporate the opioid antagonist naloxone to prevent people from crushing the tablets and injecting them. Unlike methadone treatment, buprenorphine therapy can be prescribed month-to-month and obtained at a traditional pharmacy rather than a clinic. The driving principle behind OAT/OST is the program's capacity to facilitate a resumption of stability in the person's life, while they experience reduced symptoms of withdrawal symptoms and less intense drug cravings; however, a strong euphoric effect is not experienced as a result of the treatment drug. In some countries, such as Switzerland, Austria, and Slovenia, patients are treated with slow-release morphine when methadone is deemed inappropriate due to the individual's circumstances.
Additionally, one trial aimed to assess its role in preventing actinic keratosis in organ transplant recipients. Further trials were pursued for the first two conditions, while results for the latter three were not published. Following the initial trials, research efforts centered on erythropoietic protoporphyria, and due to the epidemiology of the condition. Clinuvel secured orphan drug for afamelanotide in both the US and the EU by 2010. The first approval of afamelanotide came in May 2010 from the Italian Medicines Agency (AIFA, or Agenzia Italiana del Farmaco), followed by the European Medicines Agency (EMA) in January 2015. Both approvals were for the treatment of erythropoietic protoporphyria. The US Food and Drug Administration (FDA) granted approval in October 2019 for the use of afamelanotide as a medication to alleviate pain caused by sun exposure in individuals with erythropoietic protoporphyria. This decision was largely based on three trials involving 244 adults aged 18–74 across 22 sites in the US and Europe, which had a focus on pain-free hours in sunlight, outdoor hours under varying light conditions, and side effects. The FDA designated it as a first-in-class medication, meaning it had a novel mechanism different from previously approved medications. Between 2022 and 2023, trials were outlined to study the effects of afamelanotide on xeroderma pigmentosum and variegate porphyria, along with two additional trials exploring its impact on vitiligo. According to the register, as of April 2025, most of these trials are currently in the recruitment phase.
Sources: en.wikipedia.org
==== 3200–3299 ==== A3 Trunk Road (Robin Hood Way (South) Service Road, Kingston upon Thames) (Prescribed Routes) Order 1993 (S.I. 1993/3201) Town and Country Planning (Fees for Applications and Deemed Applications) (Scotland) Amendment Regulations 1993 (S.I. 1993/3211) Lottery Duty Regulations 1993 (S.I. 1993/3212) Plant Health (Great Britain) (Amendment) (Potatoes) Order 1993 (S.I. 1993/3213) Upper Spey and Associated Waters Protection (Renewal) Order 1993 (S.I. 1993/3216) A6 Trunk Road (Rushden and Higham Ferrers Bypass) Order 1993 (S.I. 1993/3217) A6 Trunk Road (Rushden and Higham Ferrers Bypass) (Detrunking) Order 1993 (S.I. 1993/3218) Occupational Pension Schemes (Transitional Provisions) (Amendment) Regulations 1993 (S.I. 1993/3219) Retirement Benefits Schemes (Continuation of Rights of Members of Approved Schemes) (Amendment) Regulations 1993 (S.I. 1993/3220) Retirement Benefits Schemes (Tax Relief on Contributions) (Disapplication of Earnings Cap) (Amendment) Regulations 1993 (S.I. 1993/3221) Exempt Entertainments (Variation of Monetary Limit) Order 1993 (S.I. 1993/3222) Lotteries Regulations 1993 (S.I. 1993/3223) Lotteries (Gaming Board Fees) Order 1993 (S.I. 1993/3224) Banking Coordination (Second Council Directive) (Amendment) Regulations 1993 (S.I. 1993/3225) Friendly Societies Act 1992 (Commencement No. 7 and Transitional Provisions and Savings) Order 1993 (S.I. 1993/3226) Utilities Supply and Works Contracts (Amendment) Regulations 1993 (S.I. 1993/3227) Public Services Contracts Regulations 1993 (S.I. 1993/3228) Land Registration Fees Order 1993 (S.I.
A vent site in the Cayman Trough named Beebe, which is the world's deepest known hydrothermal site at ~5,000 m (16,000 ft) below sea level, has shown sustained supercritical venting at 401 °C (754 °F) and 2.3 wt% NaCl. Although supercritical conditions have been observed at several sites, it is not yet known what significance, if any, supercritical venting has in terms of hydrothermal circulation, mineral deposit formation, geochemical fluxes or biological activity. The initial stages of a vent chimney begin with the deposition of the mineral anhydrite. Sulfides of copper, iron, and zinc then precipitate in the chimney gaps, making it less porous over the course of time. Vent growths on the order of 30 cm (1 ft) per day have been recorded. An April 2007 exploration of the deep-sea vents off the coast of Fiji found those vents to be a significant source of dissolved iron (see iron cycle).
African American Cultural Complex Contemporary Art Museum of Raleigh Gregg Museum of Art & Design at North Carolina State University Haywood Hall House & Gardens Marbles Kids Museum North Carolina Museum of Art North Carolina Museum of History North Carolina Museum of Natural Sciences North Carolina Sports Hall of Fame City of Raleigh Museum J. C. Raulston Arboretum Joel Lane House Mordecai Plantation Pope House Museum
==== MeSH D06.472.040 – adrenal cortex hormones ==== MeSH D06.472.040.502 – 17-ketosteroids MeSH D06.472.040.502.112 – androstenedione MeSH D06.472.040.502.195 – androsterone MeSH D06.472.040.502.497 – estrone MeSH D06.472.040.502.583 – etiocholanolone MeSH D06.472.040.502.620 – dehydroepiandrosterone MeSH D06.472.040.502.620.300 – dehydroepiandrosterone sulfate MeSH D06.472.040.585 – hydroxycorticosteroids MeSH D06.472.040.585.353 – 11-hydroxycorticosteroids MeSH D06.472.040.585.353.118 – aldosterone MeSH D06.472.040.585.353.237 – corticosterone MeSH D06.472.040.585.353.476 – hydrocortisone MeSH D06.472.040.585.353.500 – 18-hydroxycorticosterone MeSH D06.472.040.585.353.825 – tetrahydrocortisol MeSH D06.472.040.585.478 – 17-hydroxycorticosteroids MeSH D06.472.040.585.478.195 – cortisone MeSH D06.472.040.585.478.225 – cortodoxone MeSH D06.472.040.585.478.392 – hydrocortisone MeSH D06.472.040.585.478.782 – tetrahydrocortisol MeSH D06.472.040.585.478.865 – tetrahydrocortisone MeSH D06.472.040.585.611 – desoxycorticosterone MeSH D06.472.040.585.611.400 – 18-hydroxydesoxycorticosterone MeSH D06.472.040.585.745 – pregnenolone MeSH D06.472.040.585.745.500 – 17-alpha-hydroxypregnenolone
A haloform reaction on progesterone [57-83-0] oxidizes the 17-acetyl group into a carboxylic acid to give etienic acid [302-97-6] (2). A Schotten–Baumann reaction with tert-butylamine gives N-t-Butyl-3-oxo-4-androstene-17beta-carboxamide [131267-80-6] (3). A Lemieux–Johnson oxidation opens ring A with loss of one carbon atom. The reaction arguably involves hydroxylation of the 4–5 double bond by permanganate followed by scission of the diol by periodate. The product of the step is [190006-01-0] (4). Addition of ammonia gives a lactam-enamine [166896-74-8] (5). Catalytic hydrogenation occurs from the alpha-face [98319-24-5] (6). The reaction of the lactam with BSTFA gives an silylated imidate. Oxidation of the C1C2 position with DDQ then introduces the enone olefin group, completing the synthesis of finasteride (7).
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.